Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

by arresting mitosis and cell proliferation without impacting unrelated, normal cellular functions, thereby avoiding many of the toxicities commonly experienced by patients treated with existing anti-mitotic drugs.

About Cytokinetics

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Cytokinetics development efforts are directed to advancing multiple drug candidates through clinical trials to demonstrate proof-of-concept in humans, specifically in the areas of heart failure and cancer. Cytokinetics' cardiovascular disease program is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, recently entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. plan to conduct research with activators of cardiac myosin in order to identify potential treatments for patients with heart failure. Amgen has obtained an option for the joint development and commercialization of CK-1827452 exercisable during a defined period, the ending of which is dependent on Cytokinetics conduct of further clinical trials of CK-1827452. Cytokinetics cancer program is focused on mitotic kinesins, a family of motor proteins essential to cell division. Cytokinetics is developing two novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Ispinesib has been the subject of a broad clinical trials program comprised of nine Phase II clinical trials as well as six Phase I or Ib clinical trials. Cytokinetics plans to conduct additional clinical trials with ispinesib and is conducting a Phase I/II trial of SB-74392
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/29/2014)... 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... healthcare conferences during the third quarter, the 2014 Avondale ... Healthcare 2014 Conference.  Alexza,s corporate presentation will be webcast ... each event are below: , 2014 Avondale ... Boston , MA.  The format is ...
(Date:7/29/2014)... ROCKVILLE, Md. , July 29, 2014  Synthetic ... anti-infective biologic and drug candidates targeting specific pathogens that ... view of the unusual market activity in the Company,s ... Company in accordance with its usual practice. The Company ... unusual market activity. About Synthetic Biologics, Inc. ...
(Date:7/29/2014)... 2014 Numotion,s Board of Directors has announced that ... be the company,s new Chief Executive Officer. ... GE where he worked primarily for GE Healthcare Services, running ... $5 billion. His most recent position was as President and ... am thrilled to join Numotion," said Mike Swinford . ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2Numotion Names Mike Swinford CEO 2
... , , ... Group (MRG), the global authority on medical technology market intelligence, ... enteral feeding devices will be a key driver of the ... MRG,s new US and European Markets for Enteral Feeding ...
... , FORT COLLINS, Colo., Dec. 14 ... 250 mg (chenodiol tablets). On October 22, 2009, ... an important therapy for patients suffering from gallstones in ... disease or advanced age. , Chenodal prescriptions have started ...
Cached Medicine Technology:Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Manchester Announces Availability of Chenodal(TM) 2
(Date:7/29/2014)... 2014)A diet rich in soy may help feminine hearts, ... today in Menopause , the journal of The ... to the diet of women in Asia, produces the ... similar to Asian migrants to North America, leads to ... and switching to soy from a Western diet after ...
(Date:7/29/2014)... July 29, 2014 Daily Gossip indicates in ... method was created for any sufferer who is looking for ... The author of the new program, Sarah Summer, says that ... suffered from yeast infection, too. Actually, this is the reason ... this problem. , The Natural Cure for Yeast ...
(Date:7/29/2014)... Port Washington, New York (PRWEB) July 29, 2014 ... dedicated to protecting the rights of victims injured by ... action lawsuit has been filed by plaintiffs in Canada ... increased risk of cardiovascular events with the low ... was filed on July 22, 2014 in the Ontario ...
(Date:7/29/2014)... Regardless of the good things that ... to share those with. Love is about understanding, commitment ... Love is also about overcoming all the challenges that ... perfect relationship, women need to know how to understand ... Him program, please visit the official website at ...
(Date:7/29/2014)... of severe combat injuries threatening more than one limb, ... record of safety and effectiveness in avoiding amputation, reports ... Plastic and Reconstructive Surgery , the official medical ... (ASPS). , Experience with multiple limb salvage procedures ... success rates, with no increase in complications compared to ...
Breaking Medicine News(10 mins):Health News:Soy may help women's hearts if they start early 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:How to Reach the Heart of the Perfect Guy with "Enchant Him Program" - a Report by Daily Gossip Magazine 2Health News:Good outcomes with multiple limb salvage after severe combat injuries, reports Plastic and Reconstructive Surgery 2
... TALLAHASSEE, Fla., Aug. 12 With the recent increase in ... in these already hard economic times - do they pay the ... those who want to quit, The Florida Quitline (1-877-U-CAN-NOW) is here ... , , According to Kim Berfield, Deputy Secretary ...
... , , , , ... a leading provider of Linux-bas e d ... Systems, a national health care management company, has deployed Arkeia Network Backup. ... Goold has realized dramatic improvements in backup performance and in backup administration. ...
... Fountain Healthy Aging,Inc. announced on August 12 2009 that ... Oak Resources Limited which provides the Company,with a $5,000,000 Equity ... has the right to draw down from the Equity Line,Investment ... of 24 months. The,first tranche investment of $1,000,000 was drawn ...
... , WESTFIELD, Ind., Aug. 12 maxIT ... healthcare providers, announced the successful "Stage 6" designation of Gila ... in Silver City, New Mexico. maxIT assisted the Phoenix Health ... to support the implementation of several HIS modules. Beginning ...
... , , , ... (NYSE: HI ) -- Hillenbrand, Inc. reported net revenues of ... 2009, a $6.3 million (3.8 percent) decline from the same period in ... million (4.9 percent) decline. The difference in as-adjusted net income for the ...
... , , , ... create expensive home health care costs. Poorly designed mobility aids or ... issue only part of the need is addressed which creates mobility ... alleviated if mobility issues were detected and properly addressed. , ...
Cached Medicine News:Health News:The Time To Quit Is Now -- Free NRT Is Available 2Health News:Goold Health Systems Accelerates Backups by 5-times Using Arkeia Network Backup 2Health News:Goold Health Systems Accelerates Backups by 5-times Using Arkeia Network Backup 3Health News:Fountain Healthy Aging Inc Announces $5,000,000 Equity Line Of Credit Investment Secured 2Health News:Fountain Healthy Aging Inc Announces $5,000,000 Equity Line Of Credit Investment Secured 3Health News:maxIT Assists Medical Center to Achieve Prestigious Stage 6 Recognition 2Health News:maxIT Assists Medical Center to Achieve Prestigious Stage 6 Recognition 3Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 2Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 3Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 4Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 5Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 6Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 7Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 8Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 9Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 10Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 11Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 12Health News:Expensive Health Care: Undetected, Unmet Mobility Needs Creating Boomer & Senior Health Care Costs 2
... there is a more efficient way ... fully portable battery operated patient warming ... surgical teams with a compact and ... the entire surgical process. Its unique ...
... patient warming system consists of our ... range of blankets for use with ... clinical applications. Blankets are available for ... and paediatric sizes and a sterile ...
MAMMOMAT 3000 Nova supports high-volume screening as well as interventional diagnostics. Versatile procedural capabilities include magnification, stereotactic biopsy, needle localization, and specime...
The Synoptiscope(L-2510B) has a wide variety of functions including binocular function diagnosis and treatment....
Medicine Products: